Why STAAR Surgical Company’s (STAA) Stock Is Up 7.43%
As of Tuesday, September 29, STAAR Surgical Company’s STAA share price has surged by 7.43%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: STAAR Surgical Company (STAA)
STAAR Surgical Company STAA
$21.27
-0.99
-4.45%
October 16, 2026 4:00:00 PM
EST
Volume: 636,689
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Commentary & Analysis
Why STAAR Surgical Company’s (STAA) Stock Is Up 6.66%
As of Friday, September 25, STAAR Surgical Company’s STAA share price has surged by 6.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why STAAR Surgical Company’s (STAA) Stock Is Up 6.89%
As of Friday, August 21, STAAR Surgical Company’s STAA share price has surged by 6.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Why STAAR Surgical Company’s (STAA) Stock Is Down 6.72%
As of Monday, August 17, STAAR Surgical Company’s STAA share price has dipped by 6.72%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why STAAR Surgical Company’s (STAA) Stock Is Up 6.22%
As of Wednesday, July 29, STAAR Surgical Company’s STAA share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | STAA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,066.1 | $382.9 | 47% |
|
| Shares Out (Mil) | 51.5 | 40.9 | 48% |
|
| Institutional Ownership | 98.6% | 83.6% | 80% |
|
| Float (Mil) | 26.1 | 35.5 | 33% |
|
| Beta | 1.23 | 0.86 | 72% |
|
| Avg Daily Volume (000s) | 598 | 301 | 61% |
|
| Price Change (52-week) |
(17.6%) | 61.8% | 39% |
|
| Growth | STAA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.9% | 11.8% | 50% |
|
| Net Income (5yr) | (73.3%) | (5.5%) | 4% |
|
| EPS (5yr) | (73.1%) | 10.6% | 2 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.0%) | (15.5%) | 27% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | $0.169 | $0.840 | $1.111 | |
| Month Ago EPS | $0.168 | $0.763 | $1.024 | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | $0.169 | $0.729 | $0.989 | |
| Year/Year Chg | 5.6% | (151.8%) | (175.0%) | |
| Financials | STAA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $340 | $141 | 37% |
|
| Net Income (TTM) (Mil) | $4 | ($9) | 42% |
|
| EPS (TTM) | $0.077 | ($0.400) | 42% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 27% |
|
| Net Cash Flow (TTM) (Mil) | ($19) | $1 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $27 | 35% |
|
| Enterprise Value (Q1) (Mil) | $1,125 | $418 | 42% |
|
| Valuation | STAA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.92 | 2.50 | 67% |
|
| P/E | 276.1 | 25.8 | 99% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | STAA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.6% | 58.7% | 86% |
|
| Net Margin | 1.1% | (6.9%) | 35% |
|
| ROA | 0.8% | (12.2%) | 44% |
|
| ROE | 1.1% | (10.7%) | 37% |
|
| Liabilities to Assets | 23.1% | 47.2% | 15% |
|
| F-Score | 5 | 4 | 50% |
|
Passing Stock Screens
As of 10/16/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Dual Cash Flow Screen
Factors: Quality, Growth
An analysis that can provide advance notice that a company may be facing financial trouble, though earnings and sales appear strong.
| Performance Since Inception: | 11.2% |
| +/- S&P 500: | +3.7 |
